Table of Contents 2
List of Tables 6
List of Figures 6
Otsuka Holdings Co., Ltd. Spshot 7
Otsuka Holdings Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Otsuka Holdings Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Otsuka Holdings Co., Ltd. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combition Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combition Treatment Modalities 16
Otsuka Holdings Co., Ltd. - Pipeline Products Glance 17
Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products 17
Pre-Registration Products/Combition Treatment Modalities 17
Phase III Products/Combition Treatment Modalities 18
Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combition Treatment Modalities 19
Phase I Products/Combition Treatment Modalities 20
Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products 21
Preclinical Products/Combition Treatment Modalities 21
Otsuka Holdings Co., Ltd. - Drug Profiles 22
(carteolol hydrochloride + latanoprost) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(tipiracil hydrochloride + trifluridine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
levetiracetam 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
potinib hydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tolvaptan 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
(aripiprazole + sertraline) 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(gimeracil + oteracil + tegafur) 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
aripiprazole ER 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AVP-786 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
brexpiprazole 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
delamanid 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
biximols 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rebamipide 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(dextromethorphan + quinidine sulfate) 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OCV-501 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OPA-15406 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
OPS-2071 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
probucol 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tetomilast 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
OPA-6566 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
OPB-111001 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LPC-01 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LUAF-20513 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
OCVC-02 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OPB-111077 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OPC-108459 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
OPC-39436 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
OPC-64005 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OPC-28326 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Otsuka Holdings Co., Ltd. - Pipeline Alysis 71
Otsuka Holdings Co., Ltd. - Pipeline Products by Target 71
Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration 73
Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type 74
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action 75
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates 77
Otsuka Holdings Co., Ltd. - Dormant Projects 113
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products 114
Discontinued Pipeline Product Profiles 114
(gimeracil + oteracil + tegafur) 114
(tipiracil hydrochloride + trifluridine) 114
AVP-13358 114
AZD-2479 115
brexpiprazole 115
dasatinib 115
OCV-101 115
OPB-31121 115
OPB-51602 115
rebamipide 115
Otsuka Holdings Co., Ltd. - Company Statement 117
Otsuka Holdings Co., Ltd. - Locations And Subsidiaries 118
Head Office 118
Other Locations & Subsidiaries 118
Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 121
Disclaimer 122